Acne is a common skin disorder that can be problematic for adults as well as for adolescents. It has several key pathophysiological features such as follicular hyperkeratosis, elevated Propionibacterium acnes proliferation, and reactive inflammation, all of which should be targeted for an optimal outcome. Azelaic acid (AzA) has profound anti-inflammatory, antioxidative effects, and is bactericidal against a range of Gram-negative and Gram-positive microorganisms as well, including antibiotic-resistant bacterial strains. In addition, AzA's antikeratinizing effects are inhibitory toward comedones. AzA is effective overall in targeting multiple causes of acne and has been proven to be well tolerated in numerous clinical trials.

Ghodsi SZ, Orawa H, Zouboulis CC: Prevalence, severity, and severity risk factors of acne in high school pupils: a community-based study. J Invest Dermatol 2009;129:2136-2141.
Plewig G, Kligman AM: Acne and Rosacea, ed 3. Berlin, Springer, 2000.
Perkins AC, Maglione J, Hillebrand GG, Miyamoto K, Kimball AB: Acne vulgaris in women: prevalence across the life span. J Womens Health (Larchmt) 2012;21:223-230.
Williams C, Layton AM: Persistent acne in women: implications for the patient and for therapy. Am J Clin Dermatol 2006;7:281-290.
Jeremy AH, Holland DB, Roberts SG, Thomson KF, Cunliffe WJ: Inflammatory events are involved in acne lesion initiation. J Invest Dermatol 2003;121:20-27.
Nagy I, Pivarcsi A, Koreck A, Szell M, Urban E, Kemeny L: Distinct strains of Propionibacterium acnes induce selective human β-defensin-2 and interleukin-8 expression in human keratinocytes through toll-like receptors. J Invest Dermatol 2005;124:931-938.
Holland C, Mak TN, Zimny-Arndt U, Schmid M, Meyer TF, Jungblut PR, Bruggemann H: Proteomic identification of secreted proteins of Propionibacterium acnes. BMC Microbiol 2010;10:230.
Lomholt HB, Kilian M: Population genetic analysis of Propionibacterium acnes identifies a subpopulation and epidemic clones associated with acne. PLoS One 2010;5:e12277.
Zouboulis CC: Propionibacterium acnes and sebaceous lipogenesis: a love-hate relationship? J Invest Dermatol 2009;129:2093-2096.
Goulden V, McGeown CH, Cunliffe WJ: The familial risk of adult acne: a comparison between first-degree relatives of affected and unaffected individuals. Br J Dermatol 1999;141:297-300.
Thiboutot D, Gilliland K, Light J, Lookingbill D: Androgen metabolism in sebaceous glands from subjects with and without acne. Arch Dermatol 1999;135:1041-1045.
Mayer-da-Silva A, Gollnick H, Detmar M, Gassmuller J, Parry A, Muller R, Orfanos CE: Effects of azelaic acid on sebaceous gland, sebum excretion rate and keratinization pattern in human skin. An in vivo and in vitro study. Acta Derm Venereol Suppl (Stockh) 1989;143:20-30.
Thiboutot D: Versatility of azelaic acid 15% gel in treatment of inflammatory acne vulgaris. J Drugs Dermatol 2008;7:13-16.
Mastrofrancesco A, Ottaviani M, Aspite N, Cardinali G, Izzo E, Graupe K, Zouboulis CC, Camera E, Picardo M: Azelaic acid modulates the inflammatory response in normal human keratinocytes through PPARγ activation. Exp Dermatol 2010;19:813-820.
Briganti S, Flori E, Mastrofrancesco A, Kovacs D, Camera E, Ludovici M, Cardinali G, Picardo M: Azelaic acid reduced senescence-like phenotype in photo-irradiated human dermal fibroblasts: possible implication of PPARγ. Exp Dermatol 2013;22:41-47.
Yamasaki Y, Gallo RL: Azelaic acid gel alters kallikrein 5 and cathelicidin expression in epidermal keratinocytes, critical elements in the pathogenesis of rosacea. J Am Acad Dermatol 2010;62:AB1.
Elewski BE, Draelos Z, Dreno B, Jansen T, Layton A, Picardo M: Rosacea - global diversity and optimized outcome: proposed international consensus from the rosacea international expert group. J Eur Acad Dermatol Venereol 2011;25:188-200.
Akamatsu H, Komura J, Asada Y, Miyachi Y, Niwa Y: Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases. Arch Dermatol Res 1991;283:162-166.
Passi S, Picardo M, De Luca C, Breathnach AS, Nazzaro-Porro M: Scavenging activity of azelaic acid on hydroxyl radicals ‘in vitro'. Free Radic Res Commun 1991;11:329-338.
Passi S, Picardo M, Zompetta C, De Luca C, Breathnach AS, Nazzaro-Porro M: The oxyradical-scavenging activity of azelaic acid in biological systems. Free Radic Res Commun 1991;15:17-28.
Grange PA, Chereau C, Raingeaud J, Nicco C, Weill B, Dupin N, Batteux F: Production of superoxide anions by keratinocytes initiates P. acnes-induced inflammation of the skin. PLoS Pathog 2009;5:e1000527.
Nazzaro-Porro M, Passi S: Identification of tyrosinase inhibitors in cultures of Pityrosporum. J Invest Dermatol 1978;71:205-208.
Yamasaki K, Gallo RL: Azelaic acid (AzA) gel 15% alters kallikrein 5 in epidermal keratinocytes: critical elements in production of cathelicidin and the pathogenesis of rosacea. Dermatologist 2010;18:36-38.
Schauber J: Antimicrobial peptides, vitamin D(3) and more. How rosacea may develop (in German). Hautarzt 2011;62:815-819.
Ozkan M, Durmaz G, Sabuncu I, Saracoglu N, Akgun Y, Urer S: Clinical efficacy of topical clindamycin phosphate and azelaic acid on acne vulgaris and emergence of resistant coagulase-negative Staphylococci. Turk J Med Sci 2000;30 483-487.
Maple PA, Hamilton-Miller JM, Brumfitt W: Comparison of the in-vitro activities of the topical antimicrobials azelaic acid, nitrofurazone, silver sulphadiazine and mupirocin against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1992;29:661-668.
Farmery MR, Jones CE, Eady EA, Cove JH, Cunliffe WJ: In vitro activity of azelaic acid, benzoyl peroxide and zinc acetate against antibiotic-resistant Propionibacteria from acne patients. J Dermatolog Treat 1994;5:63-65.
Bladon PT, Burke BM, Cunliffe WJ, Forster RA, Holland KT, King K: Topical azelaic acid and the treatment of acne: a clinical and laboratory comparison with oral tetracycline. Br J Dermatol 1986;114:493-499.
Cunliffe WJ, Holland KT: Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne. Acta Derm Venereol Suppl (Stockh) 1989;143:31-34.
Bojar RA, Holland KT, Leeming JP, Cunliffe WJ: Azelaic acid: its uptake and mode of action in Staphylococcus epidermidis NCTC 11047. J Appl Bacteriol 1988;64:497-504.
Holland KT, Bojar RA: The interaction of azelaic acid with Propionibacterium acnes. J Invest Dermatol 1989;92:446A.
Holland KT, Bojar RA: Antimicrobial effects of azelaic acid. J Dermatolog Treat 1993;4:S8-S11.
King K, Leeming JP, Holland KT, Cunliffe WJ: The effect of azelaic acid on cutaneous microflora in vivo and in vitro. J Invest Dermatol 1985;84:438.
Nazzaro-Porro M, Passi S, Picardo M, Breathnach A: Possible mechanism of actions of azelaic acid on acne. J Invest Dermatol 1985;84:451.
Nazzaro-Porro M, Passi S, Picardo M, Breathnach A, Clayton R, Zina G: Beneficial effect of 15% azelaic acid cream on acne vulgaris. Br J Dermatol 1983;109:45-48.
Rach P, Topert M: Pharmacological investigations on azelaic acid. J Invest Dermatol 1986;86:327.
van Hoogdalem EJ: Transdermal absorption of topical anti-acne agents in man; review of clinical pharmacokinetic data. J Eur Acad Dermatol Venereol 1998;11(suppl 1):S13-S19; discussion S28-S29.
Farag A, Ananieva L: Acne vulgaris: ultrastructure changes after treatment with 20% azelaic acid. J Dermatolog Treat 1995;6:151-154.
Bojar RA, Cutcliffe AG, Graupe K, Cunliffe WJ, Holland KT: Follicular concentrations of azelaic acid after a single topical application. Br J Dermatol 1993;129:399-402.
Janota-Bassalik L, Wright LD: Azelaic acid utilization by a pseudomonas. J Gen Microbiol 1964;36:405-414.
Charnock C, Brudeli B, Klaveness J: Evaluation of the antibacterial efficacy of diesters of azelaic acid. Eur J Pharm Sci 2004;21:589-596.
Leeming JP, Holland KT, Bojar RA: The in vitro antimicrobial effect of azelaic acid. Br J Dermatol 1986;115:551-556.
Bojar RA, Cunliffe WJ, Holland KT: Disruption of the transmembrane pH gradient - a possible mechanism for the antibacterial action of azelaic acid in Propionibacterium acnes and Staphylococcus epidermidis. J Antimicrob Chemother 1994;34:321-330.
Bojar RA, Holland KT, Cunliffe WJ: The in-vitro antimicrobial effects of azelaic acid upon Propionibacterium acnes strain P37. J Antimicrob Chemother 1991;28:843-853.
Bojar RA, Cutcliffe AG, Graupe K, Cunliffe WJ, Holland KT: Azelaic acid: a review of its antimicrobial properties. Rec Contemp Pharmacother 1993;4:403-414.
Mayer-da Silva A: Azelaic acid: pharmacology, toxicology and mechanism of action in acne. J Dermatolog Treat 1989;1:11-15.
Gollnick H, Mayer-da-Silva A, Orfanos CE: Effects of azelaic acid on filaggrin, other cytokeratins and on the ultrastructure of human keratinocytes in vivo. J Invest Dermatol 1987;89:452.
Barbareschi M, Hendricks I, Angius A, Cattaneo M, Monti M: The anticomedonic activity of azelaic acid investigated by means of scanning electron microscopy on horny layer biopsy. J Dermatolog Treat 1991;2:55-57.
Oh CW, Myung KB: An ultrastructural study of the retention hyperkeratosis of experimentally induced comedones in rabbits: The effects of three comedolytics. J Dermatol 1996;23:169-180.
Leibl H, Stingl G, Pehamberger H, Korschan H, Konrad K, Wolff K: Inhibition of DNA synthesis of melanoma cells by azelaic acid. J Invest Dermatol 1985;85:417-422.
Detmar M, Muller R, Stadler R, Orfanos CE: Dicarboxylic acids inhibit the growth of keratinocytes in vitro (in German). Hautarzt 1986;37:625-627.
Detmar M, Mayer-da-Silva A, Stadler R, Orfanos CE: Effects of azelaic acid on proliferation and ultrastructure of mouse keratinocytes in vitro. J Invest Dermatol 1989;93:70-74.
Passi S, Picardo M, Nazzaro-Porro M, Breathnach A, Confaloni AM, Serlupi-Crescenzi G: Antimitochondrial effect of saturated medium chain length (C8-C13) dicarboxylic acids. Biochem Pharmacol 1984;33:103-108.
Melnik BC, Schmitz G, Zouboulis CC: Anti-acne agents attenuate FGFR2 signal transduction in acne. J Invest Dermatol 2009;129:1868-1877.
Gollnick H, Mayer-da-Silva A, Orfanos CE: Effects of azelaic acid on filaggrin, other cytokeratins and on the ultrastructure of human keratinocytes in vivo. J Invest Dermatol 1987;89:452.
Iraji F, Sadeghinia A, Shahmoradi Z, Siadat AH, Jooya A: Efficacy of topical azelaic acid gel in the treatment of mild-moderate acne vulgaris. Indian J Dermatol Venereol Leprol 2007;73:94-96.
Angius AG, Barbareschi M, Cattaneo M, Monti M, Caputo R: Evaluation of the anti-comedo effect of azelaic acid using the technique of horny layer biopsy and scanning electron microscopy (in Italian). G Ital Dermatol Venereol 1990;125:XXXIII-XXXVI.
Katsambas A, Graupe K, Stratigos J: Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Derm Venereol Suppl (Stockh) 1989;143:35-39.
Topert M, Rach P, Siegmund F: Pharmacology and toxicology of azelaic acid. Acta Derm Venereol Suppl (Stockh) 1989;143:14-19.
Briganti S, Camera E, Picardo M: Chemical and instrumental approaches to treat hyperpigmentation. Pigment Cell Res 2003;16:101-110.
Breathnach AC, Nazzaro-Porro M, Passi S, Zina G: Azelaic acid therapy in disorders of pigmentation. Clin Dermatol 1989;7:106-119.
Perez-Bernal A, Munoz-Perez MA, Camacho F: Management of facial hyperpigmentation. Am J Clin Dermatol 2000;1:261-268.
Rajaratnam R, Halpern J, Salim A, Emmett C: Interventions for melasma. Cochrane Database Syst Rev 2010:CD003583.
Sarkar R, Bhalla M, Kanwar AJ: A comparative study of 20% azelaic acid cream monotherapy versus a sequential therapy in the treatment of melasma in dark-skinned patients. Dermatology 2002;205:249-254.
Schallreuter KU, Wood JW: A possible mechanism of action for azelaic acid in the human epidermis. Arch Dermatol Res 1990;282:168-171.
Nazzaro-Porro M: Azelaic acid. J Am Acad Dermatol 1987;17:1033-1041.
Lemic-Stojcevic L, Nias AH, Breathnach AS: Effect of azelaic acid on melanoma cells in culture. Exp Dermatol 1995;4:79-81.
Nazzaro-Porro M, Passi S, Balus L, Breathnach A, Martin B, Morpurgo G: Effect of dicarboxylic acids on lentigo maligna. J Invest Dermatol 1979;72:296-305.
Nazzaro-Porro M, Passi S, Zina G, Breathnach AS: The depigmenting effect of azelaic acid. Arch Dermatol 1990;126:1649-1651.
Nguyen QH, Bui TP: Azelaic acid: pharmacokinetic and pharmacodynamic properties and its therapeutic role in hyperpigmentary disorders and acne. Int J Dermatol 1995;34:75-84.
Yu JS, Kim AK: Effect of combination of taurine and azelaic acid on antimelanogenesis in murine melanoma cells. J Biomed Sci 2010;17(suppl 1):S45.
Galhaup I: Azelaic acid: mode of action at cellular and subcellular levels. Acta Derm Venereol Suppl (Stockh) 1989;143:75-82.
Stamatiadis D, Bulteau-Portois MC, Mowszowicz I: Inhibition of 5-α-reductase activity in human skin by zinc and azelaic acid. Br J Dermatol 1988;119:627-632.
Draelos ZD: The rationale for advancing the formulation of azelaic acid vehicles. Cutis 2006;77:7-11.
Maru U, Michaud P, Garrigue J, Oustrin J, Rouffiac R: In vitro diffusion and skin penetration of azelaic preparations: study of correlations (in French). J Pharm Belg 1982;37:207-213.
Gollnick HP, Krautheim A: Topical treatment in acne: current status and future aspects. Dermatology 2003;206:29-36.
Del Rosso JQ, Lehman PA, Raney SG: Impact of order of application of moisturizers on percutaneous absorption kinetics: evaluation of sequential application of moisturizer lotions and azelaic acid gel 15% using a human skin model. Cutis 2009;83:119-124.
Tauber U, Weiss C, Matthes H: Percutaneous absorption of azelaic acid in humans. Exp Dermatol 1992;1:176-179.
Graupe K, Cunliffe WJ, Gollnick HP, Zaumseil RP: Efficacy and safety of topical azelaic acid (20 percent cream): an overview of results from European clinical trials and experimental reports. Cutis 1996;57:20-35.
Ortonne JP, Lacour JP: Assessment of the phototoxicity of azelaic acid using the modified method of Kaidbey and Kligman. Nouv Dermatol 1992;11:490-495.
Lankerani L, Baron ED: Photosensitivity to exogenous agents. J Cutan Med Surg 2004;8:424-431.
Ferguson J, Johnson BE: Retinoid associated phototoxicity and photosensitivity. Pharmacol Ther 1989;40:123-135.
Onoue S, Seto Y, Gandy G, Yamada S: Drug-induced phototoxicity; an early in vitro identification of phototoxic potential of new drug entities in drug discovery and development. Curr Drug Saf 2009;4:123-136.
Gould JW, Mercurio MG, Elmets CA: Cutaneous photosensitivity diseases induced by exogenous agents. J Am Acad Dermatol 1995;33:551-573, quiz 574-576.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.